CanBas Co., Ltd.
CanBas is a privately-held drug discovery company located in Shizuoka, Japan. The firm is devoted to discovery, development and commercialization of first-in-class oncology drugs targeting the G2 checkpoint, to treat life-threatening cancers better way. CanBas' leading pipeline is CBP501, a G2 checkpoint inhibitor in Phase 1 clinical development in the US. CBP501 and other molecules in the firm's pipeline are all originated from the firm's proprietary drug discovery platforms.
| Company | CanBas Co., Ltd. |
|---|---|
| URL | http://www.canbas.co.jp/ |
CanBas Co., Ltd. (Numazu, Shizuoka, "CanBas") and Takeda Pharmaceutical Company Limited (Osaka, "Takeda") today announced that both parties signed the collaboration agreement for investigational compounds for treatment of cancer, CBP501 and its backu...
CANBAS RAISES $20 MILLION
CanBas Co., Ltd. ("CanBas"), a privately held drug discovery company located in Numazu-city, Shizuoka, Japan, announced today that the company has raised approximately $20 million (JPY 2,359 million) in the 4th financing. This round, which closed Nov...
06/17/2008 | Taro InabaBoehringer Ingelheim announced an agreement to acquire Actimis Pharmaceuticals, Inc. one of our portfolio firms.
11/01/2007 | Nobuhiro Shimizu【Announcement of the Establishment of Beijing Office】
We are pleased to announce that Mitsui Ventures has opened a new office in Beijing in September2007.
07/18/2007 | Taro InabaMitsui Ventures Launching a New Approach to Seed Financing